Luhan Pharmachem Co., Ltd.

General Information on Daunorubicin HCl

A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, and used in treatment of leukemia and other neoplasms.

More  information

CAS No.:23541-50-6

Indication of Daunorubicin HCl

For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Pharmacology

Daunorubicin Hcl is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Daunorubicin Hcl may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Daunorubicin Hcl possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.

Patient Information

Daunorubicin is not recommended to patients who are pregnant and breast feeding because of the serious side
effects.

Check with your doctor immediately if you experience unusual bleeding or bruising, black stool, blood in urine or stool.

Avoid contact with persons with infections. Check with you doctor immediately if you experience fever, chill, cough or painful or painful or difficult urination.

Wash hands after you touch the medication.

Drug Interactions

Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity. Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine. Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.

Dosage reduction of Cerubidine may be required when used concurrently with other myelosuppressive agents.

Hepatotoxic medications, such as high-dose methotrexate, may impair liver function and increase the risk of toxicity.

Contraindications

Cerubidine is contraindicated in patients who have shown a hypersensitivity to it.

Disclaimer:

Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.